%A Gong Liya, Chen Hongfeng %T Molecular targeted therapy of triple-negative breast cancer %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.09.007 %P 662-665 %V 41 %N 8 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9470.shtml} %8 2014-09-25 %X Treatment options are limited for triple negative breast cancer (TNBC) since endocrinotherapy and targeted therapy that aims directly at human epidermal growth factor receptor-2 (HER-2) are ineffective. As such, in addition to surgical treatment, the mainstay of treatment of TNBC is systemic cytotoxic chemotherapy. The targeted therapy of TNBC is becoming a research hotspot because of traditional chemotherapy curative effect is not good enough. A large number of clinical trials have found that patients with TNBC can get benefits from targeted molecular strategies including polyadenosine diphosphate glucose pyrophospheralase-ribose polymerase-1 (PARP-1) inhibitor and epidermal growth factor receptor (EGFR) inhibitor.